Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Naïve Pediatric and Adult Participants with Atypical Hemolytic Uremic Syndrome (aHUS) in China
atypical hemolytic uremic
n/a - n/a
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 May 2023 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
No locations available
Participants will receive Eculizumab in a single dose vial.